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SIGNIFICANCE
Psoriasis, a chronic inflammatory skin disease, often af-
fects the nails. Nail psoriasis is an embarrassing condition 
that presents a therapeutic challenge. New treatments, 
such as the so-called biological therapies, are highly effec-
tive in treating psoriatic skin symptoms. Although many of 
these treatments have proved useful in treating nail symp-
toms, to date, their efficacy for treating nail psoriasis has 
not been determined. This study systematically analysed 
and compared the short-term efficacy of the new medica-
tions used for treating nail psoriasis, and determined their 
therapeutic ranking based on the probability of the treat-
ment improving psoriatic nail symptoms.
The comparative efficacy of registered anti-psoriatic 
biologics and small molecules in treating nail symptoms 
has not been systematically evaluated. The aim of 
this study was to perform a network meta-analysis 
to determine the efficacy of biologics and small mole-
cules in nail psoriasis. A Bayesian network meta- 
analysis of 17 randomized clinical trials (a total of 
6,053 nail psoriatic patients) was performed, compa-
ring the short-term (week 10–16) efficacy of biologics 
and small molecules in the treatment of nail psoria-
sis. All active treatments were found to be superior to 
place bo. Ixekizumab 80 mg every 4 weeks (Nail Pso-
riasis Severity Index (NAPSI) % improvement, Surfa-
ce Under the Cumulative Ranking (SUCRA)=0.92) and 
etanercept 50 mg twice weekly (probability of achiev-
ing NAPSI 50, SUCRA=0.82) proved the best short-
term treatment options. However, efficacy end-points 
in psoriasis trials were not optimized for nail assess-
ment, and outcome parameters were highly heteroge-
neous, limiting comparability. In conclusion, outcome 
parameters and efficacy endpoints of nail psoriasis tri-
als should be standardized.
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Nail psoriasis is an embarrassing condition with a high unmet medical need (1). Its negative impact regard­
ing health­related quality of life and impaired ability to 
perform daily activities are known (2). Prevalence of 
nail psoriasis is as high as 50% among psoriatic patients, 
and patients are often stigmatized (3). In addition, nail 
psoriasis can be an indicator for psoriatic arthritis (PsA) 
(4). Although a variety of therapies is available for both 
skin and nail psoriasis, treatment of nail psoriasis re­
mains a challenge (5). Recent recommendations, based 
on a dermatologist and nail expert group consensus (6), 
specify which treatments should be used as first-line in 
nail psoriasis. Usually medications used for treating skin 
psoriasis or PsA are also recommended for treating nail 
psoriasis. The comparative efficacy of these medications 
for treating both skin and joint symptoms has been ana­
lysed in several network meta­analyses (NMAs) (7–10). 
Although several randomized controlled trials (RCTs) 
have confirmed that biologics (TNF inhibitors, interleukin 
inhibitors) and novel small molecules (PDE4 inhibitors, 
JAK inhibitors) are effective in treating not only skin and 
joint, but nail also psoriasis symptoms, the comparative 
efficacy of registered anti-psoriatic biologics in treating 
nail symptoms has not been evaluated systematically. 
Similar to RCTs, NMAs are the mainstays of evidence­
based medicine, because they allow comparison of the 
effects of multiple interventions with each other by using 
advanced statistical techniques. In addition, indirect 
comparison of interventions is possible through a com­
mon comparator, as well as ranking by efficacy, thereby 
guiding guideline developers and clinicians. This study 
performed an NMA of RCTs of biological therapies in 
skin psoriasis and/or PsA with a secondary endpoint of 
nail psoriasis, to determine the efficacy of these therapies 
to treat nail psoriasis. 
MATERIALS AND METHODS
Study protocol
The NMA was registered in the International Prospective Register 
of Systematic Reviews (PROSPERO) (code CRD420191143317; 
http://dx.doi.org/10.17632/mw2b9fcrhr.1). The systematic review 
(SR) is reported according to the Preferred Reporting Items for 
Systematic Reviews and Meta­analyses (PRISMA) (11). 
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Search and eligibility
MEDLINE (via PubMed), CENTRAL and Embase were searched 
up to April 2019 for RCTs with the following search key: “nail” 
OR “psoriasis” AND random*. No filter was used. The included 
RCTs compared the efficacy of TNFα, IL-17, IL12/23, IL-23 and 
JAK and PDE4 inhibitors with placebo or active comparator in 
psoriatic patients with nail involvement. Interventions included 
biologics (ixekizumab (12, 13), etanercept (14), infliximab (15), 
ustekinumab (16, 17), tofacitinib (18–20), apremilast (21–25), 
secukinumab (26), adalimumab (27), guselkumab (28–30), 
golimumab (31), and risankizumab (32)). The severity of nail 
psoriasis was assessed by the objective scale of the Nail Psoriasis 
Severity Index (NAPSI) (33). Trial objectives were to assess target 
fingernail (usually the most severe nail, NAPSI 1–8) or overall 
fingernail (all fingernail, NAPSI 1–80).
Selection, data collection and risk of bias assessment
Trials were selected and assessed independently by 2 investigators 
(SJ, SZ) in 3 phases by title, abstract and full­texts. Interventions 
were evaluated based on NAPSI percentage improvement com­
pared with baseline, with measure of dispersion at week 10–16, 
and the number of patients achieving at least 50%, 75% or 100% 
reduction in NAPSI, with measure of dispersion at week 10–16. 
Missing values were requested from the authors of the papers via 
e­mail. RCTs were assessed with the Cochrane Risk of Bias Tool 
(34).
Statistical analysis
A Bayesian model was used to perform pairwise meta­analyses and 
NMA with the random effect model. The network model was perfor­
med under consistency assumption based on deviance information 
criterion (DIC, a measure to test model fit) since that proved to be 
equivalent to the consistency model (DIC: 63.91) and the inconsis­
tency model (DIC: 64.09). It was not possible to use node­splitting 
analysis (the comparison of direct and indirect evidence from a 
loop) to test consistency assumption, because there was insufficient 
amount of information from the comparisons in the network. Risk 
ratios (RR) and, for NAPSI 50 and mean difference (MD) for NAPSI 
percentage improvement (continuous) with 95% credible intervals 
(CrI), were used. The model was optimized and posterior samples 
were generated using the Monte­Carlo methods running in 4 chains. 
At least 20,000 adaptation iterations were set to obtain convergence 
and 10,000 stimulation iterations. Network estimates (pooled direct 
and indirect data) of each intervention compared with placebo and 
with other interventions are presented in forest plots, summarized in 
a league table (as shown in the Results section). Interventions were 
also ranked by Surface Under the Cumulative Ranking (SUCRA), 
a numerical presentation of the overall ranking, which presents a 
single number (between 0 and 1) associated with each treatment. 
The higher the SUCRA value, the more likely the intervention is 
within the top interventions. Following Puhan’s recommendations 
(35), funnel plots were created for both outcomes and Egger’s tests 
were performed to assess small­study effect. All calculations were 
performed with R (V. 3.5.2) package gemtc (V. 0.8–2) along with 
the Markov Chain Monte Carlo engine JAGS (V. 3.4.0) and STATA 
17.0 (StataCorp LLC, Texas, USA).
RESULTS
Study selection and characteristics of the included studies
The flowchart of the selection process is shown in Fig. 
1. Altogether 34 studies were included in the SR, 17 of 
which (with a total of 6,053 patients) fit the network 
(Table I). At baseline, the mean age of patients ranged 
from 41 to 54 years, males 34.4–100%, patients with PsA 
0–100%, target fingernail NAPSI 3.3–6.0 and overall 
NAPSI ranged from 18.7–47.9. Fifteen interventions, 
including placebo treatment, enrolled in the network re­
garding NAPSI percentage improvement at week 10–16 
and 9 interventions (including placebo treatment) were 
analysed regarding NAPSI 50 at week 12–16 (Fig. 2). 
The majority of the studies assessed the primary end­
points at week 10, 12 or 16.
Relative efficacy
Regarding NAPSI percentage improvement (week 
10–16), Table II summarizes the results in a league table. 
Ixekizumab 80 mg every 4 weeks and ixekizumab 80 mg 
every 2 weeks were more effective than infliximab 5 mg/
kg, ustekinumab 90 mg, ustekinumab 45 mg, adalimu­
mab 40 mg, guselkumab 50 mg, guselkumab 100 mg and 
apremilast 30 mg. Placebo was significantly worse than 
all the biologics included in the analysis.
Ranking of treatment options by efficacy
Regarding NAPSI percentage improvement (week 10–16) 
given in SUCRA, ixekizumab 80 mg every 4 weeks had 
the highest probability of being the best treatment (0.92), 
followed by ixekizumab 80 mg every 2 weeks (0.90) and 
ixekizumab 75 mg (0.78). The other interventions yielded 
lower SUCRAs (0.11–0.74); not surprisingly, placebo 
proved to be the worst option, with a SUCRA of 0.00.
Regarding NAPSI 50 (week 12–16) given in SUCRA, 
etanercept 50 mg twice and once weekly had the highest 
efficacy indicated by the ranking table probability (0.82 
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-
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and 0.77, respectively), followed by adalimumab 40 mg 
every 2 weeks (0.74). The other interventions yielded 
lower SUCRAs (0.21–0.68); not surprisingly placebo had 
the lowest probability of being the best option for treating 
nail psoriasis with a SUCRA of 0.05; Supplementary data 
available online).
Systematic review
Altogether, 34 studies were eligible for the SR. Five RCTs 
investigating the efficacy of ixekizumab 80 mg every 4 
and 2 weeks (36–42) among psoriatic patients with nail 
involve ment were included in the SR. Two RCTs were 
found with ustekinumab 45/90 mg, 2 trials with adalimu­
mab 40 mg every 2 weeks, (43) and another 2 trials with 
apremilast 30 mg twice daily (44). In addition, the SR in­
cluded 1 RCT in both groups with the following biologics: 
tofacitinib 5 and 10 mg twice daily, (45) etanercept 50 mg 
twice weekly, guselkumab 100 mg every 8 weeks, (46) 
golimumab 50 and 100 mg every 4 weeks, (31) inflixi­
mab 5 mg/kg, (47) risankizumab 90 and 180 mg (32) and 
secukinumab 150 and 300 mg (26) (see Supplementary 
data available online).





























837 (58) 43.9 ± 12.7 72.9 19.5 194 Guselkumab 100 mg Q8W1 sc. Target nail (16)
42.9 ± 12.6 74.6 18.6 191 Adalimumab 40 mg2 sc.
44.9 ± 12.9 68.4 17.2   99 Placebo




1,829 (51) 43.8 ± 12.4 71.4 18.5 420 Guselkumab 100 mg Q8W1 sc. Target nail (16)
43.0 ± 12.4 72.0 18.2 297 Adalimumab 40 mg2 sc.
43.9 ± 12.6 69.2 18.0 211 Placebo
Gooderham, et 
al. (15; 2016)
Canada; NR; NR 250 (59) NR NR NR 52 Apremilast 30 mg BID3 p.o Target nail (16)
50 Etanercept 50 mg QW4 sc.
46 Placebo




158 (65) 45 82.8   9.4 44 Ustekinumab 45 mg5 sc. Target nail (12)
44 75.8 11.3 40 Ustekinumab 90 mg5 sc.
49 83.9   3.1 18 Placebo
Jackson, et al. 
(24; 2018)
USA; NR; NR 221 (38) NR NR NR 83 Apremilast 30 mg BID3 p.o Target nail 
(NAPSI≥1) (16)Placebo




60 (100) 48.0 ± 11 57.0 NR 13 Ixekizumab 10 mg sc. Overall fingernail 
(NAPSI>0) (12)46.0 ± 15 60.0 10 Ixekizumab 25 mg sc.
46.0 ± 13 66.0 10 Ixekizumab 75 mg6 sc.
46.0 ± 13 50.0 10 Ixekizumab 150 mg6 sc.
45.0 ± 13 52.0 17 Placebo
Merola, et al. 
(18; 2017)
USA; 1 year; 
multicentre
1,196 (100) 46 78.2 24.8 487 Tofacitinib 5 mg BID3 p.o Overall nail
(16)45 77.1 23.5 476 Tofacitinib 10 mg BID3 p.o
45 75.1 21.0 233 Placebo




192 (66) 47.8 ± 11.1 74.6 15.9 40 Guselkumab 100 mg Q8W1 sc. Target nail (16)
50.1 ± 12.7 67.7 16.9 44 Guselkumab 50 mg Q8W1 sc.
48.3 ± 10.6 84.4 15.6 42 Placebo




72 (100) 46.3 ± 13.5 72.2 NR 36 Etanercept 50 mg BIW7 sc. Overall nail (12)
45.4 ± 9.2 72.7 33 Etanercept 50 mg QW4 sc.
Papp, et al. (21; 
2012)
Canada; NR; NR 352 (63) 44 63.0 NR 57 Apremilast 30 mg BID3 p.o NR (16)
55 Apremilast 20 mg BID3 p.o
55 Apremilast 10 mg BID3 p.o
54 Placebo




844 (66) 45.8 ± 13.1 67.4 24.2 363 Apremilast 30 mg BID3 p.o Target nail 
(NAPSI≥1) (16)46.5 ± 12.7 68.8 19.5 195 Placebo




411 (65) 45.3 ± 13.1 64.2 15.4 175 Apremilast 30 mg BID3 p.o Target nail 
(NAPSI≥1) (16)45.7 ± 13.4 73.0   7.7 91 Placebo
Poulin, et al. 
(27; 2013)
Canada; NR; NR 72 (50) 49.0 ± 11.4 42.9 14.3 28 Adalimumab 40 mg2 sc. Target nail (NAPSI 
0–8) (16)54.0 ± 11.4 34.8   4.3   8 Placebo
Reich, et al. (15; 
2005)
Germany; NR; NR 378 (81) 42.6 ± 11.7 69.0 31.0 240 Infliximab 5 mg/kg8 iv. Target nail (10)
43.8 ± 12.6 79.0 29.0   65 Placebo
Rich, et al. (17; 
2014)
USA; 5 year; 
multicentre
766 (71) 45.9 ± 12.3 75.8 31.3 182 Ustekinumab 45 mg9 sc. Target nail (12)
46.0 ± 10.9 77.0 38.0 187 Ustekinumab 90 mg9 sc.
45.1 ± 11.1 77.8 36.9 176 Placebo
Van de Kerkhof, 
et al. (13; 2017)
The Netherlands; 1.5 
year; multicentre
1,346 (60) 45.5 ± 12.5 71.0 22.3 229 Ixekizumab 80 mg Q2W10 sc. Total fingernail 
(NAPSI>0) (12)45.9 ± 11.6 78.0 23.2 228 Ixekizumab 80 mg Q4W11 sc.
46.3 ± 13.5 78.0 22.5 236 Etanercept 50 mg BIW7 sc.
47.5 ± 11.3 79.0 22.4 116 Placebo




266 (44) 40.7 ± 11.3 73.9   6.8 38 Tofacitinib 5 mg BID3 p.o NR (16)
41.0 ± 12.0 74.4   4.4 40 Tofacitinib 10 mg BID3 p.o
41.7 ± 13.7 70.5   9.1 38 Placebo
Demography and characteristic of the included 17 studies for NMA. 
10, 4 then every 8 weeks, 2every 2 weeks, after 80 mg at week 0, and 40 mg at week 1, 3twice daily, 4once weekly, 5at weeks 0, 4, 12, 6at weeks 0, 2, 4, 8, 12, 16, 
7twice weekly, 8at weeks 0, 2, 6 then every 8 weeks, 9at weeks 0, 4, 16, 10every 2 weeks, after a 160 mg starting dose, 11every 4 weeks, after a 160 mg starting dose. 
SD: standard deviation; NR: not reported; PsA: psoriatic arthritis; NAPSI: Nail Psoriatic Severity Index.
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For risk of bias within the individual studies and 
strength of the NMA (Supplementary data).
DISCUSSION
Summary of findings
Despite considerable progress in the treatment of pso­
riatic skin symptoms, nail psoriasis has remained a 
therapeutic challenge. Although several SRs and meta­
analyses regarding the efficacy of biological therapies 
for patients with moderate­to­severe skin psoriasis ex­
ist, there is no NMA assessing the therapeutic efficacy 
of novel anti­psoriatic medications in nail psoriasis. 
A Cochrane SR was carried out by de Vries in 2013 
(48) and SRs regarding treatment recommendations in 
nail psoriasis were also performed by Cassell (49) and 
Armstrong (50). However, many of the currently used 
anti­psoriatic therapies were not available at the time of 
these reviews, and the comparative efficacy of therapies 
was not analysed. The current SR and NMA set out to 
evaluate and compare registered biological therapies 
(TNF-inhibitors, IL-17 inhibitors, ustekinumab and IL-23 
inhibitors) and novel anti­psoriatic small molecules 
(tofacitinib and apremilast) for their therapeutic efficacy 
in nail psoriasis. The current SR included 34 RCTs and 
9,383 patients; however, only 17 RCTs (6,053 patients) 
could be evaluated in the NMA (the others had to be 
excluded mostly due to missing outcome values). The 
current study found that all active treatments were supe­
rior to placebo: both in the NAPSI percentage and NAPSI 
















































































































































































































































Comparison of efficacy of all interventions included in the network meta-analysis (NAPSI percentage improvement, at week 10–16). Shaded cells: interventions with 
regimen. Unshaded cells: efficacy values (mean difference (95% confidence interval; 95% CI) between interventions. Statistically significant differences are in bold. 
1Every 4 weeks, 2every 2 weeks, 3twice weekly.  
Fig. 2. Network of interventions. The edges demonstrate direct (head-to-
head) comparisons of interventions. The nodes represent interventions. The 
width of the edges and the size of the nodes are proportional to the sample size 
of the trials. (a) Nail Psoriasis Severity Index (NAPSI) percentage improvement 
from baseline at week 10–16. Fifteen interventions including placebo were 
analysed. (b) Number of patients achieving at least 50% reduction in NAPSI 
(NAPSI 50). Nine interventions including placebo were analysed.
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50 analysis. For NAPSI percentage improvement, the 
IL­17 inhibitor ixekizumab 80 mg every 4 weeks and 
every 2 weeks ranked first and second, respectively, fol­
lowed by ixekizumab 75 mg. Interestingly, the IL­12/23 
inhibitor ustekinumab ranked second and third to last. 
Surprisingly, the IL­23 inhibitor guselkumab also ranked 
worse than the TNF-inhibitor adalimumab, although in 
head­to­head comparison RCTs guselkumab was found 
to be superior to adalimumab in treating skin symptoms 
(both regarding IGA and PASI 90 at week 16) (29). When 
NAPSI 50 was used as the outcome measure, etanercept 
50 mg twice and once weekly ranked first and second, 
respectively, and adalimumab 40 mg twice weekly 
scored third. It must be emphasized, however, that, in 
this analysis, only RCTs with etanercept, adalimumab, 
tofacitinib and apremilast could be included; there was 
no trial with IL­17, IL­12/23 or IL­23 inhibitors. In the 
current NMA ixekizumab was associated with the highest 
efficacy for nail psoriasis, while both the IL-23 guselku­
mab and the IL­12/23 ustekinumab ranked surprisingly 
low. In a recent meta­analysis, Sawyer et al (51) found 
that brodalumab, ixekizumab, guselkumab and risanki­
zumab had the highest benefit for skin symptoms. This 
suggests that the efficacy of biologics may be different 
in treating skin and nail psoriasis. This is probably due 
to the different pathogenesis of skin and nail psoriasis 
symptoms, as well as to the different mode of action of 
biologics, as shown by the opposing skin and nail results 
in the guselkumab vs adalimumab trial (29). As nail (es­
pecially matrix) psoriasis is known to be associated with 
PsA, it is tempting to assume that systemic anti­psoriatic 
agents may perform similarly in nail and PsA studies. In 
a recent meta­analysis secukinumab was found superior 
in terms of ACR20 and ACR50 to ustekinumab, while for 
PASI 75 the ranking was opposite (52). In a more recent 
NMA, however, ustekinumab 90 mg had almost the same 
efficacy as ixekizumab (Q2: 80 mg every 2 weeks, after 
a 160 mg starting dose Q4: 80 mg every 4 weeks, after 
a 160 mg starting dose) for ACR20 response and PASI 
75 response during induction therapy, while ustekinumab 
45 mg was less efficacious both in treating skin and joint 
symptoms (53). According to the recommendation of the 
National Psoriasis Foundation, (54) ustekinumab, adali­
mumab, etanercept and infliximab should be regarded as 
the most appropriate therapeutic option for nail psoria­
sis. These results provide additional information when 
choosing the optimal treatment for psoriatic patients who 
are candidates for systemic therapy. In case clearance of 
nail symptoms is of considerable importance, according 
to the current results, the best option would be the IL­17 
inhibitor ixekizumab, whereas ustekinumab or guselku­
mab are potentially less effective.
Study limitations
Several points must be taken into consideration when 
analysing these results. First, extensive heterogeneity of 
outcome measure reporting was found concerning nail 
psoriasis in the RCTs reviewed. At least 7 different nail 
scoring systems were used, making the comparison of the 
results rather difficult. We chose the 2 most commonly 
used assessment tools: (i) proportional improvement 
of the NAPSI score (NAPSI percentage) and (ii) the 
likelihood of achieving 50% reduction in the NAPSI 
score (NAPSI 50). RCTs, using different nail assess­
ment meth ods (such as modified NAPSI, Psoriasis Nail 
Severity Score, Nail Area Severity), had to be excluded 
from the NMA in order to meet the transitivity condi­
tion. This led to considerable reduction in the number of 
RCTs in the NMA, and resulted in the exclusion of some 
therapies from the analysis. For example, a recent trial 
investigating the efficacy of secukinumab (55), with a 
total of 304 psoriatic patients, had to be excluded from 
the current analysis, since nail severity and improvement 
was assessed by a composite fingernail score. In addition, 
several RCTs had to be excluded from the analysis due to 
missing outcome values; measure of dispersion or central 
tendency (for a complete list of reasons for exclusion from 
the network meta­analysis see the Supplementary data 
available online). For example this was the reason why 
another RCT with secukinumab, although it showed 
excellent efficacy for nail psoriasis (26), could not be 
included in the current analysis. In an attempt to elaborate 
on the results of the 16 RCTs not included in the network 
analysis, missing values were requested from the cor­
responding authors of the original trials; however, none 
of them responded.
Secondly, in the current NMA we could only include 
short-term observations regarding the efficacy of bio­
logics in nail psoriasis. This may limit the relevance of 
the study, as nail psoriasis improvement is considerably 
slower than that of the skin. Most analysed RCTs were 
designed to assess the efficacy of the medications on 
skin symptoms, for which almost complete response can 
be expected within 10–16 weeks. Thus, in most RCTs, 
this time period was chosen as the assessment time. In 
case of nail symptoms, it may take significantly longer 
(26–52 weeks) to reach optimal results, and between 
week 10 and 16 nail psoriasis severity values may change 
dynamically. This could lead to potential bias in favour 
of drugs with fast onset of action (e.g. TNF- and IL-17 
inhibitors), and trials with later (week 16) assessment 
time­points. Based on the methodology of NMA, a com­
mon comparator arm is needed for the evaluation of the 
efficacy of the therapeutic agents. As most psoriasis trials 
are placebo­controlled cross­over studies, the comparator 
arm is terminated after the primary endpoint (usually at 
week 10–16). Therefore, unless the trial was designed 
to assess week 24–52 efficacy as the primary endpoint, 
long­term study results could not be used in the NMA.
It is noteworthy that in the case of the highest ranked 
therapy (ixekizumab), nail assessments were performed 
at week 12; this suggests that assessment time within the 
J. Szebényi et al.6/7
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10–16-week range is probably not the most significant 
factor determining short-term nail treatment efficacy. 
To date, there have been very few trials evaluating nail 
psoriasis as a primary end­point in a placebo­controlled, 
prospective manner (26, 43, 47). In these RCTs long­
term (week 32–52) data were indeed significantly better 
than short­term (week 10–16) results, and additional 
improvement after week 16 was between 5 and 32% of 
the total therapeutic result.
Thirdly, there was some diversity among the studies; 
for example, in terms of the presence of PsA, poten­
tially resulting in further bias. In previous RCTs, which 
included patients both with and without PsA, NAPSI 
improvement was similar, regardless of PsA status (26, 
47). This makes it rather unlikely that the presence or 
absence of PsA significantly influenced the results, al-
though this cannot be ruled out entirely. 
In conclusion, the results of this study have a number of 
implications for clinical practice and for further research.
Regarding clinical practice, the results provide 
addition al information when choosing treatment for pso­
riatic patients who are candidates of systemic therapy. If 
clearance of nail symptoms is of considerable importance, 
the best option would be the IL­17 inhibitor ixekizumab, 
whereas ustekinumab or guselkumab are potentially less 
effective. 
Regarding research, the results of future head­to­head 
comparison RCTs may be used to verify the current 
results. The outcome parameters and efficacy endpoints 
of clinical trials in the field of nail psoriasis should be 
standardized.
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